الإحصائيات الأساسية
| CIK | 1472012 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Immunome, Inc.
SEC Filings (Chronological Order)
توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.
| August 6, 2025 |
Exhibit 10.1 IMMUNOME, INC 2024 INDUCEMENT PLAN EFFECTIVE AS OF: OCTOBER 3, 2024 AMENDED BY THE COMPENSATION COMMITTEE AS OF: MAY 8, 2025 1. GENERAL. (a) Eligible Award Recipients. The only persons eligible to receive grants of Awards under this Plan are individuals who satisfy the standards for inducement grants under Nasdaq Marketplace Rule 5635(c)(4) or 5635(c)(3), if applicable, and the relate |
|
| August 6, 2025 |
Exhibit 10.2 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. FIRST AMENDMENT TO LEASE This FIRST AMENDMENT TO LEASE (“First Amendment”) is made and entered into on June 11, 2025 (the “Effective Date”), by and b |
|
| August 6, 2025 |
Immunome Reports Second Quarter 2025 Financial Results and Provides Business Update Exhibit 99.1 Immunome Reports Second Quarter 2025 Financial Results and Provides Business Update 8/6/2025 BOTHELL, Wash. – Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the quarter ended June 30, 2025 and provided a business update. “Immunome made substantial progress in |
|
| August 6, 2025 |
Exhibit 10.3 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY […***…], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. THIRD AMENDMENT TO LEASE This THIRD AMENDMENT TO LEASE (“Third Amendment”) is made and entered into on June 11, 2025 (the “Effective Date”), by and between NITROGEN PROPCO 2020, |
|
| August 6, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number: 001 |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025 Immunome, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39580 77-0694340 (state or other jurisdiction of incorporation) (Commission File Numb |
|
| June 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2025 Immunome, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39580 77-0694340 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| May 12, 2025 |
Immunome Reports First Quarter 2025 Financial Results and Provides Business Update Exhibit 99.1 Immunome Reports First Quarter 2025 Financial Results and Provides Business Update 5/12/2025 BOTHELL, Wash. – Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the quarter ended March 31, 2025 and provided a business update. “Immunome continued to build momentum |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 Immunome, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39580 77-0694340 (state or other jurisdiction of incorporation) (Commission File Number) |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 |
|
| April 24, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitt |
|
| April 24, 2025 |
SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 19, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2025 Immunome, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39580 77-0694340 (state or other jurisdiction of incorporation) (Commission File Numb |
|
| March 19, 2025 |
Amended and Restated Insider Trading Policy Exhibit 19.1 Immunome, Inc. Amended and Restated Insider Trading Policy I. Introduction During the course of your relationship with Immunome, Inc. (together with its consolidated subsidiaries, “Immunome” or the “Company”), you may receive material information that is not yet publicly available (“material nonpublic information”) about the Company or about other publicly traded companies with which |
|
| March 19, 2025 |
Lease dated December 16, 2024, by and between the Company and Nitrogen Propco 2020, L.P. Exhibit 10.28 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY […***…], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. ALLOY INNOVATION CENTER LEASE This Lease (the “Lease”), dated as of the date set forth in Section 1 of the Summary of Basic Lease Information (the “Summary”), below, is made by |
|
| March 19, 2025 |
As filed with the Securities and Exchange Commission on March 19, 2025 As filed with the Securities and Exchange Commission on March 19, 2025 Registration No. |
|
| March 19, 2025 |
Exhibit 10.11 IMMUNOME, INC 2024 INDUCEMENT PLAN EFFECTIVE AS OF: OCTOBER 3, 2024 1. GENERAL. (a) Eligible Award Recipients. The only persons eligible to receive grants of Awards under this Plan are individuals who satisfy the standards for inducement grants under Nasdaq Marketplace Rule 5635(c)(4) or 5635(c)(3), if applicable, and the related guidance under Nasdaq IM 5635-1. A person who previous |
|
| March 19, 2025 |
Exhibit 10.7 Immunome, Inc. Executive Stock Option Grant Notice (2020 Equity Incentive Plan) Immunome, Inc. (the “Company”), pursuant to its 2020 Equity Incentive Plan (the “Plan”), has granted to you (“Optionholder”) an option to purchase the number of shares of the Common Stock set forth below (the “Option”). Your Option is subject to all of the terms and conditions as set forth herein and in th |
|
| March 19, 2025 |
Exhibit 10.27 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY […***…], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SECOND AMENDMENT TO LEASE This SECOND AMENDMENT TO LEASE (“Second Amendment”) is made and entered into on December 16 , 2024 (the “Effective Date”), by and between NITROGEN PROP |
|
| March 19, 2025 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 Immunome, Inc. Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.0001 per share to be issued pursuant to the Immunome, Inc. 2020 Equity |
|
| March 19, 2025 |
Exhibit 10.24 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. AMENDMENT #1 TO MASTER LICENSE AGREEMENT THIS AMENDMENT #1 TO MASTER LICENSE AGREEMENT (the “Amendment”), made and entered into this 16th day of Oct |
|
| March 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-39580 IMMUNOME, INC. (Exact name of registrant |
|
| March 19, 2025 |
Immunome Reports Full Year 2024 Financial Results and Provides Business Update Exhibit 99.1 Immunome Reports Full Year 2024 Financial Results and Provides Business Update 3/19/2025 · Topline data for Phase 3 RINGSIDE study of varegacestat in progressing desmoid tumors expected in second half of 2025. · First patient dosed in Phase 1 clinical trial evaluating IM-1021, a ROR1-targeted ADC. · IND submitted in March 2025 for IM-3050, a FAP-targeted radioligand therapy. · Project |
|
| February 4, 2025 |
EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that a single Schedule 13D (or any amendment thereto) relating to the Common Stock of Immunome, Inc. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13D. Dated: February 4, 2025 Immunome Aggregator, LP By: Enavate Sciences GP, LLC its General Partner By: /s/ Ja |
|
| February 3, 2025 |
JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) EX-99.1 2 p25-0385exhibit991.htm JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of fi |
|
| January 30, 2025 |
Immunome Announces Proposed Public Offering of Common Stock Exhibit 99.1 Immunome Announces Proposed Public Offering of Common Stock January 29, 2025 BOTHELL, Wash. – Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced its plans to commence an underwritten public offering, subject to market and other conditions, to issue and sell $125.0 million |
|
| January 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2025 Immunome, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39580 77-0694340 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| January 30, 2025 |
Exhibit 1.1 Immunome, Inc. 19,354,839 Shares of Common Stock, par value $0.0001 per share Underwriting Agreement January 29, 2025 J.P. Morgan Securities LLC TD Securities (USA) LLC Leerink Partners LLC Guggenheim Securities, LLC As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 TD Securities (USA) L |
|
| January 30, 2025 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-277036 Prospectus Supplement (To prospectus dated February 13, 2024) 19,354,839 shares Common stock We are offering 19,354,839 shares of our common stock. Our common stock is traded on the Nasdaq Capital Market under the symbol “IMNM.” On January 29, 2025, the last reported sale price of our common stock on the Nasdaq Capita |
|
| January 30, 2025 |
Immunome Announces Pricing of Upsized Public Offering of Common Stock Exhibit 99.2 Immunome Announces Pricing of Upsized Public Offering of Common Stock January 29, 2025 BOTHELL, Wash. – Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the pricing of an underwritten public offering of 19,354,839 shares of its common stock at a price to the public of $ |
|
| January 30, 2025 |
Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Immunome, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(1) Fees to be Paid Equit |
|
| January 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2025 Immunome, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39580 77-0694340 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| January 29, 2025 |
TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| January 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 21, 2025 Immunome, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39580 77-0694340 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| January 23, 2025 |
Relocation Offer Letter dated January 20, 2025, by and between the Company and Max Rosett. Exhibit 10.1 January 20, 2025 Max Rosett [email protected] Re: Relocation Package Dear Max: Congratulations! In recognition of your continued hard work, dedication and loyalty to the success of Immunome, Inc. (the “Company”), the Company is pleased to offer you the relocation package described below. Capitalized terms used but not defined in this letter have the respective meanings given to the |
|
| November 22, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Immunome, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.00 |
|
| November 22, 2024 |
As filed with the securities and Exchange Commission on November 22, 2024 TABLE OF CONTENTS As filed with the securities and Exchange Commission on November 22, 2024 Registration No. |
|
| November 14, 2024 |
EX-99.1 2 tm2427858d4ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock of Immuno |
|
| November 14, 2024 |
IMNM / Immunome, Inc. / Redmile Group, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Immunome, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 45257U108 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| November 13, 2024 |
Exhibit 10.2 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. AMENDMENT NO. 2 TO LICENSE AGREEMENT This AMENDMENT NO. 2 TO LICENSE AGREEMENT (the “Amendment No. 2”) is dated as of August 7, 2024 (the “Amendment |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| November 13, 2024 |
Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update Exhibit 99.1 Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update 11/13/2024 BOTHELL, Wash. –Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on the development of first-in-class and best-in-class targeted oncology therapies, today announced financial results for the third quarter ended September 30, 2024, and provided a business update. “Immunome contin |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2024 Immunome, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39580 77-0694340 (state or other jurisdiction of incorporation) (Commission File N |
|
| October 29, 2024 |
Exhibit 2.1 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. ASSET PURCHASE AGREEMENT by and among Zentalis Pharmaceuticals, Inc., Zeno Management, Inc. and Immunome, Inc. Dated as of October 25, |
|
| October 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2024 Immunome, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39580 77-0694340 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| October 29, 2024 |
Exhibit 4.1 STOCK ISSUANCE AGREEMENT This Stock Issuance Agreement (“Agreement”) is entered into as of October 25, 2024, by and between Zentalis Pharmaceuticals, Inc., a Delaware corporation having offices at 10275 Science Center Drive, Suite 200, San Diego, CA 92121 (“Zentalis”), and Immunome, Inc. a Delaware corporation having an office at 18702 North Creek Parkway, Suite 100, Bothell, WA |
|
| October 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2024 Immunome, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39580 77-0694340 (state or other jurisdiction of incorporation) (Commission File Num |
|
| October 8, 2024 |
Exhibit 4.7 STOCK ISSUANCE AGREEMENT This Stock Issuance Agreement (“Agreement”) is entered into as of August 7, 2024, by and between Bristol-Myers Squibb Company, a Delaware corporation having offices at Route 206 and Province Line Road, Princeton, New Jersey 08543 (“BMS”), and Immunome, Inc., a Delaware corporation having an office at 18702 N. Creek Parkway, Suite 100, Bothell, Washington |
|
| October 8, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Immunome, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.00 |
|
| October 8, 2024 |
IMMUNOME, INC 2024 INDUCEMENT PLAN EFFECTIVE AS OF: OCTOBER 3, 2024 Exhibit 99.1 IMMUNOME, INC 2024 INDUCEMENT PLAN EFFECTIVE AS OF: OCTOBER 3, 2024 1. GENERAL. (a) Eligible Award Recipients. The only persons eligible to receive grants of Awards under this Plan are individuals who satisfy the standards for inducement grants under Nasdaq Marketplace Rule 5635(c)(4) or 5635(c)(3), if applicable, and the related guidance under Nasdaq IM 5635-1. A person who previousl |
|
| October 8, 2024 |
As filed with the securities and Exchange Commission on October 8, 2024 TABLE OF CONTENTS As filed with the securities and Exchange Commission on October 8, 2024 Registration No. |
|
| August 21, 2024 |
IMNM / Immunome, Inc. / Barchas Isaac Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Immunome, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 45257U108 (CUSIP Number) Isaac Barchas 21 E. 93rd Street #2 New York, NY 10128 (Name, Address and Telephone Number of Person Authorized to Receive No |
|
| August 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2024 Immunome, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39580 77-0694340 (state or other jurisdiction of incorporation) (Commission File Num |
|
| August 12, 2024 |
Immunome Reports Second Quarter 2024 Financial Results and Provides Business Update Exhibit 99.1 Immunome Reports Second Quarter 2024 Financial Results and Provides Business Update 08/12/2024 BOTHELL, Wash. – Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on the development of first-in-class and best-in-class targeted oncology therapies, today announced financial results for the second quarter ended June 30, 2024, and provided a business update. “Immunome is focus |
|
| August 12, 2024 |
Employment Offer Letter dated June 17, 2024, by and between Immunome, Inc. and Phil Tsai. Exhibit 10.1 May 24, 2024 Phil Tsai Re:Immunome, Inc. Employment Offer Dear Phil: On behalf of Immunome, Inc. (the “Company”), I am pleased to offer you employment as Chief Technical Officer of the Company. The purpose of this letter agreement is to set forth the terms of the offer and your employment should you accept the offer. Certain capitalized terms are defined in Section 11 below. 1.Positio |
|
| August 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00 |
|
| June 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2024 Immunome, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39580 77-0694340 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| May 14, 2024 |
Immunome Reports First Quarter 2024 Financial Results and Provides Business Update Exhibit 99.1 Immunome Reports First Quarter 2024 Financial Results and Provides Business Update - Integration of AL102 and IM-1021 completed - Topline data for Phase 3 RINGSIDE trial of AL102 expected in second half of 2025 - IM-1021 and IM-3050 IND submissions expected in first quarter of 2025 BOTHELL, Wash. – Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-c |
|
| May 14, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Immunome, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(3) |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 |
|
| May 14, 2024 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-277036 PROSPECTUS SUPPLEMENT (To prospectus dated February 13, 2024) $200,000,000 Common Stock We have entered into a sales agreement, dated May 14, 2024, or the ATM Agreement, with TD Securities (USA) LLC, or TD Cowen, relating to shares of our common stock offered by this prospectus supplement and accompanying prospectus. |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2024 Immunome, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39580 77-0694340 (state or other jurisdiction of incorporation) (Commission File Number |
|
| May 14, 2024 |
Sales Agreement, by and between Immunome, Inc. and TD Securities (USA) LLC, dated May 14, 2024. Immunome, Inc. $200,000,000 SALES AGREEMENT May 14, 2024 TD Securities (USA) LLC (dba TD Cowen) 1 Vanderbilt Avenue New York, New York 10017 Ladies and Gentlemen: Immunome, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with TD Securities (USA) LLC (“TD Cowen”), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to time during th |
|
| April 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2024 Immunome, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39580 77-0694340 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| April 26, 2024 |
SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 26, 2024 |
SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2024 Immunome, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39580 77-0694340 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| April 3, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Immunome, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.00 |
|
| April 3, 2024 |
As filed with the securities and Exchange Commission on April 3, 2024 TABLE OF CONTENTS As filed with the securities and Exchange Commission on April 3, 2024 Registration No. |
|
| April 3, 2024 |
As filed with the securities and Exchange Commission on April 3, 2024 TABLE OF CONTENTS As filed with the securities and Exchange Commission on April 3, 2024 Registration No. |
|
| April 3, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Immunome, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.00 |
|
| March 28, 2024 |
Exhibit 10.19 November 30, 2023 Max Rosett Re:Immunome, Inc. Amended and Restated Employment Offer Terms Dear Max: On behalf of Immunome, Inc. (the “Company”), I am pleased to offer you continuing employment as Senior Vice President (“SVP”), Operations of the Company on the amended terms set forth herein. The purpose of this letter agreement is to set forth the amended terms of your employment sho |
|
| March 28, 2024 |
Immunome Reports Full-Year 2023 Financial Results and Provides Update on Recently Acquired Assets Exhibit 99.1 Immunome Reports Full-Year 2023 Financial Results and Provides Update on Recently Acquired Assets - Topline data for Phase 3 RINGSIDE trial of AL102 expected in first quarter of 2025 - IM-1021 and IM-3050 IND filings expected in first quarter of 2025 - Current cash expected to fund activities into 2026 BOTHELL, Wash. – Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on |
|
| March 28, 2024 |
Separation Agreement effective October 2, 2023, by and between the Registrant and Dennis Giesing. Exhibit 10.32 October 2, 2023 By Hand and Email Dennis Giesing [email protected] Re:Separation Agreement Dear Dennis: This letter agreement (“Agreement”) sets forth the agreement concerning the end of your employment with Immunome, Inc. (the “Company”). Payment and provision of the Severance Benefits (defined below) is contingent on your agreement to and compliance with the terms of this Agreeme |
|
| March 28, 2024 |
Incentive Compensation Recoupment Policy. Exhibit 97 IMMUNOME, INC. INCENTIVE COMPENSATION RECOUPMENT POLICY 1.INTRODUCTION The Board of Directors (the “Board”) of Immunome, Inc., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Policy (this “Policy”) providing for the Company’s recoupment of Recoverable Incentive Com |
|
| March 28, 2024 |
Asset Purchase Agreement dated December 22, 2023, by and between the Registrant and Atreca, Inc. Exhibit10.37 Execution Version ASSET PURCHASE AGREEMENT by and between Atreca, Inc. and Immunome, Inc. Dated as of December 22, 2023 Table of Contents Page ARTICLE 1 DEFINITIONS 1 1.1 Certain Defined Terms 1 1.2 Interpretation 11 ARTICLE 2 SALE AND PURCHASE 12 2.1 Sale and Purchase; Transferred Assets; Assumed Liabilities 12 2.2 Closing Consideration 14 2.3 Closing 15 2.4 Third Party Consents 15 2 |
|
| March 28, 2024 |
Exhibit 10.21 November 30, 2023 Robert Lechleider, M.D. Re:Immunome, Inc. Amended and Restated Employment Offer Terms Dear Bob: On behalf of Immunome, Inc. (the “Company”), I am pleased to offer you continuing employment as Chief Medical Officer of the Company on the amended terms set forth herein. The purpose of this letter agreement is to set forth the amended terms of your employment should you |
|
| March 28, 2024 |
Exhibit 10.18 December 14, 2023 Bruce Turner Re:Immunome, Inc. Amended and Restated Employment Offer Terms Dear Bruce: On behalf of Immunome, Inc. (the “Company”), I am pleased to offer you continuing employment as Chief Strategy Officer of the Company on the amended terms set forth herein. The purpose of this letter agreement is to set forth the amended terms of your employment should you accept |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-39580 IMMUNOME, INC. (Exact name of registrant |
|
| March 28, 2024 |
Exhibit 10.30 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. ZENTALIS PHARMACEUTICALS, INC. AND IMMUNOME, INC. LICENSE AGREEMENT January 5, 2024 TABLE OF CONTENTS Page 1.DEFINITIONS 1 2.LICENSE AND TRANSFER OF |
|
| March 28, 2024 |
Consulting Agreement dated October 2, 2023, by and between the Registrant and Dennis Giesing. Exhibit 10.33 Execution Copy IMMUNOME, INC. CONSULTING AGREEMENT CONSULTING AGREEMENT effective as of October 2, 2023 (the “Effective Date”) between Immunome, Inc., a Delaware corporation (the “Company”), and the undersigned consultant to the Company (the “Consultant”). Background: The parties wish to enter into this Agreement to set forth the basis on which the Consultant will perform consulting |
|
| March 28, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2024 Immunome, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39580 77-0694340 (state or other jurisdiction of incorporation) (Commission File Numb |
|
| March 28, 2024 |
Exhibit 10.23 February 7, 2024 Kinney Horn Re:Immunome, Inc. Employment Offer Dear Kinney: On behalf of Immunome, Inc. (the “Company”), I am pleased to offer you employment as Chief Business Officer of the Company. The purpose of this letter agreement is to set forth the terms of the offer and your employment should you accept the offer. Certain capitalized terms are defined in Section 11 below. 1 |
|
| March 28, 2024 |
Exhibit 21.1 IMMUNOME, INC. Name of Subsidiary Jurisdiction MorphImmune Inc. Delaware |
|
| March 28, 2024 |
Employment Offer dated November 30, 2023, by and between the Registrant and Philip Roberts. Exhibit 10.22 November 30, 2023 Philip Roberts Re:Immunome, Inc. Employment Offer Dear Phil: On behalf of Immunome, Inc. (the “Company”), I am pleased to offer you employment as Chief Technical Officer of the Company. The purpose of this letter agreement is to set forth the terms of the offer and your employment should you accept the offer. Certain capitalized terms are defined in Section 11 below |
|
| March 28, 2024 |
Exhibit 10.17 November 30, 2023 Sandra Stoneman Re:Immunome, Inc. Amended and Restated Employment Offer Terms Dear Sandra: On behalf of Immunome, Inc. (the “Company”), I am pleased to offer you continuing employment as Chief Legal Officer of the Company on the amended terms set forth herein. The purpose of this letter agreement is to set forth the amended terms of your employment should you accept |
|
| March 28, 2024 |
Employment Offer dated April 26, 2021, by and between the Registrant and Bob Lapetina. Exhibit 10.38 April 26, 2021 Robert Lapetina 708 Julian Drive Collegeville, PA 19426 Dear Bob, On behalf of Immunome, Inc. (the “Company”), I am pleased to make this conditional offer of employment to you as our Controller. The purpose of this letter agreement is to set forth the terms of the offer and your employment should you accept the offer. 1. Position: Duties: a. Your position will be as a |
|
| March 28, 2024 |
Exhibit 10.34 October 3, 2023 By Hand and Email Purnanand Sarma [email protected] Re:Separation Agreement Dear Sarma: This letter agreement (“Agreement”) sets forth the agreement concerning the end of your employment with Immunome, Inc. (the “Company”). Payment and provision of the Severance Benefits (defined below) is contingent on your agreement to and compliance with the terms of this Agreemen |
|
| March 28, 2024 |
Exhibit 10.20 November 30, 2023 Jack Higgins Re:Immunome, Inc. Amended and Restated Employment Offer Terms Dear Jack: On behalf of Immunome, Inc. (the “Company”), I am pleased to offer you continuing employment as Chief Scientific Officer of the Company on the amended terms set forth herein. The purpose of this letter agreement is to set forth the amended terms of your employment should you accept |
|
| March 28, 2024 |
Exhibit 10.16 AMENDMENT NO. 1 TO EXECUTIVE EMPLOYMENT AGREEMENT This AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT (this “Amendment”) is made and entered into as of December 1, 2023 (the “Effective Date”) by and between Immunome, Inc., a Delaware corporation (the “Company”), and Clay B. Siegall, Ph.D., an individual resident in the State of Washington (the “Executive”) (the Company and the Executive are |
|
| March 26, 2024 |
Exhibit 10.1 Certain information marked as [***] has been excluded from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. LICENSE AGREEMENT between AYALA PHARMACEUTICALS, INC. and BRISTOL-MYERS SQUIBB COMPANY Certain information marked as [***] has been excluded from this exhibit because it is both (i) not material and (ii) would be com |
|
| March 26, 2024 |
Exhibit 99.1 Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala BOTHELL, Wash. – Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the successful completion of its purchase of AL102 and related drug candidate AL101 from Ayala Pharmaceuticals, |
|
| March 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2024 Immunome, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39580 77-0694340 (state or other jurisdiction of incorporation) (Commission File Numb |
|
| February 14, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2024 Immunome, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39580 77-0694340 (State or other jurisdiction of incorporation) (Commission File N |
|
| February 14, 2024 |
Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Immunome, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(1) Fees to be Paid Equit |
|
| February 14, 2024 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-277036 Prospectus supplement (To prospectus dated February 13, 2024) 10,000,000 shares Common stock We are offering 10,000,000 shares of our common stock. Our common stock is traded on the Nasdaq Capital Market under the symbol “IMNM.” On February 13, 2024, the last reported sale price of our common stock on the Nasdaq Capit |
|
| February 14, 2024 |
Exhibit 1.1 Immunome, Inc. 10,000,000 Shares of Common Stock, par value $0.0001 per share Underwriting Agreement February 13, 2024 J.P. Morgan Securities LLC Cowen and Company, LLC Leerink Partners LLC Guggenheim Securities, LLC As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Cowen a |
|
| February 13, 2024 |
Exhibit 4.3 STOCK ISSUANCE AGREEMENT This Stock Issuance Agreement (“Agreement”) is entered into as of January 5, 2024, by and between Zentalis Pharmaceuticals, Inc., a Delaware corporation having offices at 1359 Broadway, Suite 801, New York, NY 10018 (“Zentalis”), and Immunome, Inc. a Delaware corporation having an office at 665 Stockton Drive, Suite 300, Exton, PA 19341 (“Immunome”). The capita |
|
| February 13, 2024 |
Exhibit 99.2 RISK FACTORS An investment in shares of our common stock involves a high degree of risk. You should carefully consider the following risk factors, together with the information contained in our Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission, or SEC, on March 16, 2023 and our Quarterly Report on Form 10-Q for the quart |
|
| February 13, 2024 |
Calculation of Filing Fee Tables Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Immunome, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry F |
|
| February 13, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2024 Immunome, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39580 77-0694340 (State or other jurisdiction of incorporation) (Commission File N |
|
| February 13, 2024 |
As filed with the Securities and Exchange Commission on February 13, 2024 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on February 13, 2024 Registration No. |
|
| February 13, 2024 |
Form of Indenture, between the Registrant and one or more trustees to be named. Exhibit 4.4 IMMUNOME, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [·], 20 Debt Securities Table Of Contents Page article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificate 8 Sect |
|
| February 13, 2024 |
Exhibit 99.1 IMMUNOME’S BUSINESS Overview We are a biopharmaceutical company focused on the development of targeted oncology therapies. We believe that the pursuit of novel or underexplored targets will be central to the next generation of transformative therapies. For that reason, we pursue therapeutics that we believe have best-in-class or first-in-class potential. Our goal is to establish a bro |
|
| February 13, 2024 |
TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| February 13, 2024 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate. Exhibit 4.8 Immunome, Inc. and , As Warrant Agent Form of Preferred Stock Warrant Agreement Dated As Of Immunome, Inc. Form of Preferred Stock Warrant Agreement This Preferred Stock Warrant Agreement (this “Agreement”), dated as of [●], between Immunome, Inc., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing |
|
| February 13, 2024 |
Form of Common Stock Warrant Agreement and Warrant Certificate. Exhibit 4.7 Immunome, Inc. and , As Warrant Agent Form of Common Stock Warrant Agreement Dated As Of Immunome, Inc. Form of Common Stock Warrant Agreement This Common Stock Warrant Agreement (this “Agreement”), dated as of [●], between Immunome, Inc., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing under the laws of [●] and hav |
|
| February 13, 2024 |
Form of Debt Securities Warrant Agreement and Warrant Certificate. Exhibit 4.9 Immunome, Inc. and , As Warrant Agent Form of Debt Securities Warrant Agreement Dated As Of Immunome, Inc. Form of Debt Securities Warrant Agreement This Debt Securities Warrant Agreement (this “Agreement”), dated as of [·], between Immunome, Inc., a Delaware corporation (the “Company”), and [·], a [corporation] [national banking association] organized and existin |
|
| February 12, 2024 |
EX-99.1 2 a021224b.htm EXHIBIT A Exhibit A Pursuant to the instructions in Item 6 of Schedule 13G, the following lists the identity of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Alpine Partners (BVI), L.P.* *Entity that beneficially owned 5% or greater of the outstanding shares of the security class being reported on this Schedule |
|
| February 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Amendment No. 5 Under the Securities Exchange Act of 1934 IMMUNOME, INC. (Name of Issuer) Common stock, $0.0001 par value per share (Title of Class of Securities) 45257U108 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu |
|
| February 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 5, 2024 Immunome, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39580 77-0694340 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| February 6, 2024 |
Exhibit 2.1 CONFIDENTIAL EXECUTION VERSION ASSET PURCHASE AGREEMENT by and between Ayala Pharmaceuticals, Inc. and Immunome, Inc. Dated as of February 5, 2024 Table of Contents Page 1. Definitions 1 2. Purchase and Sale of Assets 20 2.1 Acquired Assets 20 2.2 Assumed Liabilities 21 2.3 Excluded Liabilities 21 2.4 Assets Incapable of Transfer 21 3. Consider |
|
| February 6, 2024 |
Exhibit 99.1 Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals – AL102 is a small molecule gamma secretase inhibitor with a differentiated clinical profile – BOTHELL, WA and MONMOUTH JUNCTION, NJ, Feb. 6, 2023 – Immunome, Inc. (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer the |
|
| February 6, 2024 |
Form of Ayala Pharmaceuticals, Inc. Support Agreement, dated February 5, 2024. Exhibit 10.1 CONFIDENTIAL EXHIBIT A SUPPORT AGREEMENT This Support Agreement (this “Agreement”) is made as of February 5, 2024, by and among Ayala Pharmaceuticals, Inc., a Delaware corporation (the “Company”), Immunome, Inc., a Delaware corporation (“Purchaser”), and the Person or Persons set forth on the signature page hereto (“Stockholder”). Capitalized terms used but not otherwise defined herei |
|
| February 2, 2024 |
Exhibit 99.4 Immunome, Inc. Stock Option Grant Notice Immunome, Inc. (the “Company”), pursuant to the terms of this Stock Option Grant Notice (this “Grant Notice”) and the Stock Option Agreement attached hereto, hereby grants to you (“Optionholder”) an option to purchase the number of shares of the Common Stock set forth below (the “Option”) as an inducement material to you entering into employmen |
|
| February 2, 2024 |
As filed with the Securities and Exchange Commission on February 2, 2024 As filed with the Securities and Exchange Commission on February 2, 2024 Registration No. |
|
| February 2, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Immunome, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.0001 |
|
| February 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2024 Immunome, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39580 77-0694340 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| January 11, 2024 |
Immunome Corporate Presentation January 11, 2024 Exhibit 99.1 Immunome Corporate Presentation January 11, 2024 2 IMMUNOME Disclaimer and Forward - Looking Statements Disclosures For the purposes of this notice, the “presentation” that follows shall mean and include the slides that follow, the oral pres ent ation of the slides by members of management of Immunome, Inc. (“Immunome”) or any person on its behalf, any question - and - answer session |
|
| January 11, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2024 Immunome, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39580 77-0694340 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2024 Immunome, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39580 77-0694340 (State or other jurisdiction of incorporation) (Commission File Num |
|
| January 8, 2024 |
Exhibit 99.1 Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform - Exclusive worldwide license agreement for preclinical ROR1 ADC, on track to submit IND in 1Q 2025 - - Proprietary ADC platform enhances Immunome’s development of next-generation ADC programs - - Zentalis to receive up-front payment of $35 million in cash and Immunome common stock |
|
| January 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 2, 2024 Immunome, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39580 77-0694340 (State or other jurisdiction of incorporation) (Commission File Num |
|
| December 29, 2023 |
Separation Agreement by and between the Company and Corleen Roche, dated December 22, 2023. Exhibit 10.1 December 21, 2023 By Email Corleen Roche Re: Separation Agreement Dear Corleen: This letter agreement (“Agreement”) sets forth the agreement concerning the end of your employment with Immunome, Inc. (the “Company”). Payment and provision of the Severance Benefits (defined below) is contingent on your agreement to and compliance with the terms of this Agreement. Terms not defi |
|
| December 29, 2023 |
Exhibit 10.2 IMMUNOME, INC. CONSULTING AGREEMENT CONSULTING AGREEMENT (“Agreement”) effective as of January 2, 2024 (the “Effective Date”) between Immunome, Inc., a Delaware corporation (the “Company”), and the undersigned consultant to the Company (the “Consultant”). Background: The parties wish to enter into this Agreement to set forth the basis on which the Consultant will perform consulting se |
|
| December 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2023 Immunome, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39580 77-0694340 (State or other jurisdiction of incorporation) (Commission File N |
|
| December 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2023 Immunome, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39580 77-0694340 (State or other jurisdiction of incorporation) (Commission File N |
|
| November 22, 2023 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS Exhibit 99.3 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS On June 29, 2023, Immunome, Inc. (Immunome) entered into an Agreement and Plan of Merger and Reorganization (Merger Agreement) with Morphimmune Inc., (Morphimmune) and Ibiza Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Immunome (Merger Sub). Upon the terms and subject to the satisfaction of the cond |
|
| November 22, 2023 |
Report of Independent Auditors Exhibit 99.1 Report of Independent Auditors The Board of Directors and the Stockholders Morphimmune, Inc. Report on the Audit of the Financial Statements Opinion We have audited the financial statements of Morphimmune, Inc., which comprise the balance sheets as of December 31, 2022 and 2021, and the related statements of operations and comprehensive loss, convertible preferred stock and stockholde |
|
| November 22, 2023 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2023 Immunome, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39580 77-0694340 (State or other jurisdiction of incorporation) (Commission Fil |
|
| November 22, 2023 |
Exhibit 99.2 Morphimmune Inc. Condensed Balance Sheets (unaudited) (in thousands, except share and per share amounts) September 30, December 31, 2023 2022 Assets Current assets: Cash and cash equivalents $ 10,068 $ 7,151 Prepaid expenses and other current assets 191 117 Total current assets 10,259 7,268 Property and equipment, net 646 11 Total assets $ 10,905 $ 7,279 Liabilities, Convertible Prefe |
|
| November 22, 2023 |
Immunome, Inc. 665 Stockton Drive, Suite 300 Exton, PA 19341 Immunome, Inc. 665 Stockton Drive, Suite 300 Exton, PA 19341 November 22, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Tamika N. Sheppard Re: Immunome, Inc. Registration Statement on Form S-3 File No. 333-275598 Acceleration Request Requested Date: November 27, 2023 Requested Time: 4:00 PM Eastern Time Ladies |
|
| November 16, 2023 |
As filed with the Securities and Exchange Commission on November 16, 2023 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on November 16, 2023 Registration No. |
|
| November 16, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Immunome, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.00 |
|
| November 15, 2023 |
Immunome Corporate Presentation November 15, 2023 Exhibit 99.1 Immunome Corporate Presentation November 15, 2023 2 IMMUNOME Disclaimer and Forward - Looking Statements Disclosures For the purposes of this notice, the “presentation” that follows shall mean and include the slides that follow, the oral pres ent ation of the slides by members of management of Morphimmune , Inc. (“ Morphimmune ”) and Immunome, Inc. (“Immunome”) or any person on their |
|
| November 15, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2023 Immunome, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39580 77-0694340 (State or other jurisdiction of incorporation) (Commission File N |
|
| November 9, 2023 |
Third Amended and Restated Non-Employee Director Compensation Policy, effective October 27, 2023. Exhibit 10.2 IMMUNOME, INC. THIRD AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Each member of the Board of Directors (the “Board”) of Immunome, Inc. (the “Company”) who is a non- employee director of the Company (each such member, a “Non-Employee Director”) will receive the compensation described in this Third Amended and Restated Non-Employee Director Compensation Policy (the “P |
|
| November 9, 2023 |
Exhibit 10.1 IMMUNOME, INC. 2020 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: SEPTEMBER 18, 2020 APPROVED BY THE STOCKHOLDERS: SEPTEMBER 22, 2020 AMENDED BY THE BOARD OF DIRECTORS: AUGUST 23, 2023 APPROVED BY THE STOCKHOLDER: SEPTEMBER 29, 2023 AMENDED BY THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS: OCTOBER 27, 20231 1 Per the terms of the Plan, Applicable Law and applicable l |
|
| November 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 Immunome, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39580 77-0694340 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| November 9, 2023 |
Exhibit 99.1 Immunome Reports Third Quarter 2023 Financial Results - Completed merger with Morphimmune and concurrent $125 million private placement investment with leading institutional investors - - Clay B. Siegall, Ph.D., former co-founder & CEO of Seagen, Inc., appointed as Chairman and CEO - - Bob Lechleider, M.D., appointed as Chief Medical Officer – - Jean-Jacques Bienaimé, former CEO of Bi |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2023 Immunome, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39580 77-0694340 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| November 2, 2023 |
As filed with the Securities and Exchange Commission on November 1, 2023 As filed with the Securities and Exchange Commission on November 1, 2023 Registration No. |
|
| October 12, 2023 |
Joint Filing Agreement among the Reporting Entities, dated as of October 2, 2023. EX-99.1 2 ff2590247991-immunome.htm Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that a single Schedule 13D (and any amendment thereto) relating to the Common Stock of Immunome, Inc. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13D. Immunome Aggregator, LP By: /s/ James P. Boylan Name: James P. Boylan |
|
| October 12, 2023 |
IMNM / Immunome Inc / Redmile Group, LLC - SC 13G Passive Investment SC 13G 1 tm2328282d1sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Immunome, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 45257U108 (CUSIP Number) October 2, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig |
|
| October 12, 2023 |
EX-99.1 2 tm2328282d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock of Immuno |
|
| October 12, 2023 |
IMNM / Immunome Inc / Immunome Aggregator, LP Activist Investment SC 13D 1 ff259024713d-immunome.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Immunome, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45257U108 (CUSIP Number) Immunome Aggregator, LP 106 W 56th Street 8th Floor New York, New York, 10019 Attention: Jam |
|
| October 12, 2023 |
IMNM / Immunome Inc / Barchas Isaac Activist Investment SC 13D 1 immunome13d.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Immunome, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 45257U108 (CUSIP Number) Isaac Barchas 1807 W. 11th Street, Austin, TX 78703 (Name, Address and Telephone Number of Person Au |
|
| October 12, 2023 |
Letter Agreement, dated as of June 29, 2023. EX-99.3 3 ff2590247993-immunome.htm Exhibit 99.3 Confidential IMMUNOME, INC. 665 Stockton Drive Exton, Pennsylvania 19341 June 29, 2023 Enavate Sciences, LP 106 W 56th Street (8th Floor) New York, NY 10019 Re: Board Appointment Rights Ladies and Gentlemen: Reference is hereby made to the subscription agreement, dated as of June 29, 2023 (the “Subscription Agreement”), by and between Immunome, Inc. |
|
| October 12, 2023 |
IMNM / Immunome Inc / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Immunome, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45257U108 (CUSIP Number) October 2, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua |
|
| October 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2023 Immunome, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39580 77-0694340 (state or other jurisdiction of incorporation) (Commission File |
|
| October 4, 2023 |
Exhibit 3.2 CERTIFICATE OF MERGER MERGING IBIZA MERGER SUB, INC., A DELAWARE CORPORATION WITH AND INTO MORPHIMMUNE INC., A DELAWARE CORPORATION October 2, 2023 Pursuant to Title 8, Section 251 of the General Corporation Law of the State of Delaware Pursuant to Title 8, Section 251(c) of the Delaware General Corporation Law (the “DGCL”), the undersigned corporation executed the following Certificat |
|
| October 4, 2023 |
Exhibit 99.1 Immunome and Morphimmune Announce Successful Completion of Merger with $125 Million PIPE to Develop Novel Targeted Cancer Therapies 10/03/2023 · Clay B. Siegall, Ph.D., former co-founder & CEO of Seagen, Inc., appointed as Chairman and CEO · $125 million private placement investment completed with leading institutional investors will support cash runway expected to extend into Q1 2026 |
|
| October 4, 2023 |
Exhibit 3.3 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF IMMUNOME, INC. It is hereby certified that: FIRST: The name of the corporation is Immunome, Inc. (the “Corporation”). SECOND: The Amended and Restated Certificate of Incorporation of the Corporation is hereby amended by adding new Article IX as follows: IX. A. The liability of the officers for monetary dam |
|
| October 4, 2023 |
Exhibit 3.4 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF IMMUNOME, INC. It is hereby certified that: FIRST: The name of the corporation is Immunome, Inc. (the “Corporation”). SECOND: Section A of Article IV of the Amended and Restated Certificate of Incorporation of the Corporation is hereby amended and restated in its entirety to read as follows: A. The Corpora |
|
| September 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 21, 2023 Immunome, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39580 77-0694340 (state or other jurisdiction of incorporation) (Commission File |
|
| September 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 21, 2023 Immunome, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39580 77-0694340 (state or other jurisdiction of incorporation) (Commission File |
|
| August 28, 2023 |
PROPOSED MERGER YOUR VOTE IS VERY IMPORTANT TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-273792 PROPOSED MERGER YOUR VOTE IS VERY IMPORTANT To the Stockholders of Immunome, Inc. and Morphimmune Inc.: Immunome, Inc. (Immunome) and Morphimmune Inc. (Morphimmune) have entered into an Agreement and Plan of Merger and Reorganization, dated June 29, 2023, as may be amended from time to time (Merger Agreement |
|
| August 25, 2023 |
Exhibit 10.47 MorphImmune Inc. June 24, 2022 Max Rosett 1068 E Kensington Ave Salt Lake City, UT 84105 Re: Amended and Restated Employment Terms Dear Max: As you know, you are currently employed by MorphImmune Inc. (the “Company”) pursuant to that certain offer letter dated January 1, 2022 (the “Offer Letter”). The Company is hereby amended and restating the terms of your employment with the Compa |
|
| August 25, 2023 |
Exhibit 10.48 MorphImmune Inc. 26 April, 2022 Jack Higgins Re: Employment Terms Dear Jack: MorphImmune Inc. (the “Company”) is pleased to offer you employment effective as of 1 May 2022 (the “Start Date”), on the terms set forth herein. Position Your initial position will be Chief Scientific Officer, responsible for performing such duties as are assigned to you from time to time. Of course, the Co |
|
| August 25, 2023 |
Exhibit 107 CALCULATION OF FILING FEE TABLE FORM S-4 (Form Type) IMMUNOME, INC. (Exact Name of Registrant as Specified in its Charter) Table I: Newly Registered and Carry Forward Securities Security Security Fee Amount Proposed Maximum Fee Rate Amount of Type Class Calculation Registered1 Maximum Offering Price Registration Title or Carry Offering Fee Forward Price Per Rule Unit Equity Common Stoc |
|
| August 25, 2023 |
As filed with the Securities and Exchange Commission on August 25, 2023 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on August 25, 2023 Registration No. |
|
| August 25, 2023 |
Form of Proxy Card for Special Meeting of Immunome, Inc. Exhibit 99.7 Signature [PLEASE SIGN WITHIN BOX] Date Signature (Joint Owners) Date TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: KEEP THIS PORTION FOR YOUR RECORDS DETACH AND RETURN THIS PORTION ONLY THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. V22721-TBD For Against Abstain ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! IMMUNOME, INC. IMMUNOME, INC. 665 STOCKTON DRIVE SUITE 300 EXTON, PA 193 |
|
| August 25, 2023 |
Immunome, Inc. 665 Stockton Drive, Suite 300 Exton, Pennsylvania 19341 Immunome, Inc. 665 Stockton Drive, Suite 300 Exton, Pennsylvania 19341 August 25, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 RE: Immunome, Inc. Registration Statement on Form S-4 File No. 333-273792 Request for Acceleration of Effectiveness Ladies and Gentlemen: In accordance with Rule 461 promulgated un |
|
| August 25, 2023 |
Exhibit 10.46 MorphImmune Inc. May 9, 2023 Bruce Turner 980 Idlewild Road Gladwyne, PA 19035 [email protected] Re: Employment Terms Dear Bruce: MorphImmune Inc. (the “Company”) is pleased to offer you employment effective as of March 1, 2023 (the “Start Date”), on the terms set forth in this letter agreement (“Agreement”). Position Your position will be Chief Strategy Officer, Executive Vic |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00 |
|
| August 9, 2023 |
Immunome Reports Second Quarter 2023 Financial Results Exhibit 99.1 Immunome Reports Second Quarter 2023 Financial Results Exton, PA – August 9, 2023 – Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics to improve patient care, today reported financial results for the second quarter ended June 30, 2023 and provided a corporate update. “W |
|
| August 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2023 Immunome, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39580 77-0694340 (state or other jurisdiction of incorporation) (Commission File Numb |
|
| August 8, 2023 |
Exhibit 107 CALCULATION OF FILING FEE TABLE FORM S-4 (Form Type) IMMUNOME, INC. (Exact Name of Registrant as Specified in its Charter) Table I: Newly Registered and Carry Forward Securities Security Security Fee Amount Proposed Maximum Fee Rate Amount of Type Class Calculation Registered1 Maximum Offering Price Registration Title or Carry Offering Fee Forward Price Per Rule Unit Equity Common Stoc |
|
| August 8, 2023 |
Consent of Isaac Barchas to be named as a director. Exhibit 99.3 Consent to be Named as a Director Nominee In connection with the filing by Immunome, Inc. of the Registration Statement on Form S-4 (the “Registration Statement”) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of direc |
|
| August 8, 2023 |
Morphimmune, Inc. 2020 Equity Incentive Plan. Exhibit 10.44 MORPHIMMUNE INC. 2020 EQUITY INCENTIVE PLAN Approved by the Board of Directors: February 5, 2020 Approved by the Stockholders: February 15, 2020 Amended by the Board of Directors: April 16, 2020 Amended by the Stockholders: April 16, 2020 Amended by the Board of Directors: October 21, 2021 Amended by the Stockholders: November 4, 2021 Amended By the Board of Directors: February 4, 20 |
|
| August 8, 2023 |
Form of Morphimmune, Inc. Indemnification Agreement. Exhibit 10.49 MORPHIMMUNE, INC. INDEMNIFICATION AGREEMENT This Indemnification Agreement (this “Agreement”) is dated as of , and is between Morphimmune Inc., a Delaware corporation (together with its subsidiaries, the “Company”), and (“Indemnitee”). RECITALS A. Indemnitee’s service to the Company substantially benefits the Company. B. Individuals are reluctant to serve as directors or officers of |
|
| August 8, 2023 |
Consent of Stifel, Nicolaus & Company, Incorporated. Exhibit 99.1 Consent of Stifel, Nicolaus & Company, Incorporated Stifel, Nicolaus & Company, Incorporated (“Stifel”) hereby consents to the inclusion of our opinion letter, dated June 28, 2023, to the Board of Directors (in its capacity as such) of Immunome, Inc. (“Immunome”) included as Annex B, and to the references thereto under the captions “Summary – Opinion of Immunome’s Financial Advisor,” |
|
| August 8, 2023 |
Consent of Clay Siegall, Ph.D. to be named as a director. Exhibit 99.2 Consent to be Named as a Director Nominee In connection with the filing by Immunome, Inc. of the Registration Statement on Form S-4 (the “Registration Statement”) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of direc |
|
| August 8, 2023 |
Consent of James Boylan to be named as a director. Exhibit 99.4 Consent to be Named as a Director Nominee In connection with the filing by Immunome, Inc. of the Registration Statement on Form S-4 (the “Registration Statement”) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of direc |
|
| August 8, 2023 |
Exhibit 10.42 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. MASTER SPONSORED RESEARCH AGREEMENT This Master Sponsored Research Agreement (“Agreement”), made as of February 1, 2022 (“Effective Date”), by and a |
|
| August 8, 2023 |
Exhibit 10.43 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. MASTER LICENSE AGREEMENT THIS MASTER LICENSE AGREEMENT is made and entered into as of January 19th, 2022 (“Effective Date”), by and between PURDUE R |
|
| August 8, 2023 |
MORPHIMMUNE INC. 2020 EQUITY INCENTIVE PLAN STOCK OPTION AGREEMENT Unless otherwise defined herein, the terms defined in the 2020 Equity Incentive Plan (the “Plan”) shall have the same defined meanings in this Stock Option Agreement (the “Option Agreement”). I. NOTICE OF STOCK OPTION GRANT Name: Address: The undersigned Participant has been granted an Option to purchase Common Stock of the Company |
|
| August 8, 2023 |
Subsidiaries of the registrant. Exhibit 21.1 Name of Subsidiary Jurisdiction Ibiza Merger Sub, Inc. Delaware |
|
| August 8, 2023 |
As filed with the Securities and Exchange Commission on August 8, 2023 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on August 8, 2023 Registration No. |
|
| July 7, 2023 |
EX-1.02 Exhibit 1.02 Confidential Execution Version SUPPORT AGREEMENT This SUPPORT AGREEMENT (this “Agreement”) is made as of June 29, 2023, by and between MORPHIMMUNE INC., a Delaware corporation (the “Company”), and the Person or Persons set forth on Schedule A hereto (“Stockholder”). Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to such term |
|
| July 7, 2023 |
IMNM / Immunome Inc / MorphImmune Inc. - SC 13D Activist Investment SC 13D SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Immunome, Inc. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 45257U108 (CUSIP Number) Morphimmune Inc. 101 Foundry Dr. Suite 1200, West Lafayette, Indiana 47906 Attn: Clay Siegall, Ph.D., Chief Executive Officer Copies to: Tom Coll Dyla |
|
| July 7, 2023 |
EX-1.03 Exhibit 1.03 Execution Version EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is entered into as of June 28, 2023 between Immunome, Inc., a Delaware corporation (the “Company’’), and Clay B. Siegall, Ph.D. (“Executive’’) (collectively referred to as the “Parties” or individually referred to as a “Party”). R E C I T A L S WHEREAS, Executive is currentl |
|
| July 7, 2023 |
EX-1.01 Exhibit 1.01 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER AND REORGANIZATION by and among: IMMUNOME, INC., a Delaware corporation; IBIZA MERGER SUB, INC., a Delaware corporation; and MORPHIMMUNE INC., a Delaware corporation Dated as of June 29, 2023 TABLE OF CONTENTS Page SECTION 1. DESCRIPTION OF TRANSACTION 2 1.1 The Merger 2 1.2 Effects of the Merger 2 1.3 Closing; Effective Time 3 1. |
|
| July 5, 2023 |
Exhibit 99.1 Morphimmune and Immunome Combined Corporate Presentation July 2023 MORPHIMMUNE + IMMUNOME 2 Disclaimer and Forward-Looking Statements Disclosures For the purposes of this notice, the “presentation” that follows shall mean and include the slides that follow, the oral presentation of the slides by members of management of Morphimmune, Inc. (“Morphimmune”) and Immunome, Inc. (“Immunome”) |
|
| July 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 5, 2023 Immunome, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39580 77-0694340 (state or other jurisdiction of incorporation) (Commission File Number |
|
| July 5, 2023 |
Exhibit 99.1 Morphimmune and Immunome Combined Corporate Presentation July 2023 MORPHIMMUNE + IMMUNOME 2 Disclaimer and Forward-Looking Statements Disclosures For the purposes of this notice, the “presentation” that follows shall mean and include the slides that follow, the oral presentation of the slides by members of management of Morphimmune, Inc. (“Morphimmune”) and Immunome, Inc. (“Immunome”) |
|
| July 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 5, 2023 Immunome, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39580 77-0694340 (state or other jurisdiction of incorporation) (Commission File Number |
|
| June 29, 2023 |
Filed by Immunome, Inc. Pursuant to Rule 425 under the Securities Act of 1933, as amended and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: Immunome, Inc. (Commission File No. 001-39580) Date: June 29, 2023 The following tweet was made available in connection with the transaction beginning on June 29, 2023. June 29, 2023 1:55 p.m. ET Tw |
|
| June 29, 2023 |
Form of Subscription Agreement, dated June 29, 2023 Exhibit 10.4 SUBSCRIPTION AGREEMENT Immunome, Inc. 665 Stockton Drive, Suite 300 Exton, Pennsylvania 19341 Ladies and Gentlemen: This Subscription Agreement (this “Subscription Agreement”) is being entered into as of June 29, 2023, by and between Immunome, Inc., a Delaware corporation (“IMNM”), and each of the undersigned investors (each an “Investor”), in connection and concurrently with the Agre |
|
| June 29, 2023 |
Form of Lock-Up Agreement, dated June 29, 2023. Exhibit 10.3 EXECUTION VERSION Lock-Up Agreement June 29, 2023 Ladies and Gentlemen: The undersigned (the “Stockholder”) understands that: (i) IMMUNOME INC., a Delaware corporation (“Parent”), has entered into an Agreement and Plan of Merger and Reorganization, dated as of June 29, 2023 (the “Merger Agreement”), with MORPHIMMUNE INC., a Delaware corporation (the “Company”), and Ibiza Merger Sub, I |
|
| June 29, 2023 |
Exhibit 10.4 SUBSCRIPTION AGREEMENT Immunome, Inc. 665 Stockton Drive, Suite 300 Exton, Pennsylvania 19341 Ladies and Gentlemen: This Subscription Agreement (this “Subscription Agreement”) is being entered into as of June 29, 2023, by and between Immunome, Inc., a Delaware corporation (“IMNM”), and each of the undersigned investors (each an “Investor”), in connection and concurrently with the Agre |
|
| June 29, 2023 |
Form of Morphimmune, Inc. Stockholder Support Agreement, dated June 29, 2023 Exhibit 10.2 EXECUTION VERSION SUPPORT AGREEMENT This Support Agreement (this “Agreement”) is made as of June 29, 2023, by and between Immunome Inc., a Delaware corporation (“Parent”), and the Person or Persons set forth on Schedule A hereto (“Stockholder”). Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to such terms in the Merger Agreement. WH |
|
| June 29, 2023 |
Employment Agreement, dated June 28, 2023, by and between Immunome, Inc. and Clay B. Siegall, Ph.D. Exhibit 10.5 Execution Version EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is entered into as of June 28, 2023 between Immunome, Inc., a Delaware corporation (the “Company”), and Clay B. Siegall, Ph.D. (“Executive”) (collectively referred to as the “Parties” or individually referred to as a “Party”). R E C I T A L S WHEREAS, Executive is currently the Chie |
|
| June 29, 2023 |
Exhibit 99.2 CONFIDENTIAL - DO NOT DISTRIBUTE Morphimmune and Immunome Combined Corporate Presentation June 2023 CONFIDENTIAL - DO NOT DISTRIBUTE M O R P H I M M U N E + I M M U N O M E 2 Disclaimer and Forward-Looking Statements Disclosures For the purposes of this notice, the “presentation” that follows shall mean and include the slides that follow, the oral presentation of the slides by members |
|
| June 29, 2023 |
Exhibit 99.1 Immunome and Morphimmune Announce Definitive Merger Agreement and Simultaneous Private Placement Investment of $125 Million to Develop Targeted Cancer Therapies · The combined company, which will operate as Immunome, will feature a synergistic platform expected to enable the development of best-in-class targeted cancer therapies across multiple modalities · Clay B. Siegall, Ph.D., cur |
|
| June 29, 2023 |
Form of Immunome, Inc. Stockholder Support Agreement, dated June 29, 2023 Exhibit 10.1 Confidential Execution Version SUPPORT AGREEMENT This Support Agreement (this “Agreement”) is made as of June 29, 2023, by and between Morphimmune Inc., a Delaware corporation (the “Company”), and the Person or Persons set forth on Schedule A hereto (“Stockholder”). Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to such terms in the |
|
| June 29, 2023 |
Form of Lock-Up Agreement, dated June 29, 2023 Exhibit 10.3 EXECUTION VERSION Lock-Up Agreement June 29, 2023 Ladies and Gentlemen: The undersigned (the “Stockholder”) understands that: (i) IMMUNOME INC., a Delaware corporation (“Parent”), has entered into an Agreement and Plan of Merger and Reorganization, dated as of June 29, 2023 (the “Merger Agreement”), with MORPHIMMUNE INC., a Delaware corporation (the “Company”), and Ibiza Merger Sub, I |
|
| June 29, 2023 |
Exhibit 99.1 Immunome and Morphimmune Announce Definitive Merger Agreement and Simultaneous Private Placement Investment of $125 Million to Develop Targeted Cancer Therapies · The combined company, which will operate as Immunome, will feature a synergistic platform expected to enable the development of best-in-class targeted cancer therapies across multiple modalities · Clay B. Siegall, Ph.D., cur |
|
| June 29, 2023 |
Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER AND REORGANIZATION by and among: IMMUNOME, INC., a Delaware corporation; IBIZA MERGER SUB, INC., a Delaware corporation; and MORPHIMMUNE INC., a Delaware corporation Dated as of June 29, 2023 Table of Contents Page Section 1. DESCRIPTION OF TRANSACTION 2 1.1 The Merger 2 1.2 Effects of the Merger 2 1.3 Clo |
|
| June 29, 2023 |
Form of Immunome, Inc. Stockholder Support Agreement, dated June 29, 2023. Exhibit 10.1 Confidential Execution Version SUPPORT AGREEMENT This Support Agreement (this “Agreement”) is made as of June 29, 2023, by and between Morphimmune Inc., a Delaware corporation (the “Company”), and the Person or Persons set forth on Schedule A hereto (“Stockholder”). Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to such terms in the |
|
| June 29, 2023 |
Employment Agreement, dated June 28, 2023, by and between Immunome, Inc. and Clay B. Siegall, Ph.D. Exhibit 10.5 Execution Version EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is entered into as of June 28, 2023 between Immunome, Inc., a Delaware corporation (the “Company”), and Clay B. Siegall, Ph.D. (“Executive”) (collectively referred to as the “Parties” or individually referred to as a “Party”). R E C I T A L S WHEREAS, Executive is currently the Chie |
|
| June 29, 2023 |
Form of Morphimmune, Inc. Stockholder Support Agreement, dated June 29, 2023. Exhibit 10.2 EXECUTION VERSION SUPPORT AGREEMENT This Support Agreement (this “Agreement”) is made as of June 29, 2023, by and between Immunome Inc., a Delaware corporation (“Parent”), and the Person or Persons set forth on Schedule A hereto (“Stockholder”). Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to such terms in the Merger Agreement. WH |
|
| June 29, 2023 |
Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER AND REORGANIZATION by and among: IMMUNOME, INC., a Delaware corporation; IBIZA MERGER SUB, INC., a Delaware corporation; and MORPHIMMUNE INC., a Delaware corporation Dated as of June 29, 2023 Table of Contents Page Section 1. DESCRIPTION OF TRANSACTION 2 1.1 The Merger 2 1.2 Effects of the Merger 2 1.3 Clo |
|
| June 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2023 Immunome, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39580 77-0694340 (state or other jurisdiction of incorporation) (Commission File Numbe |
|
| June 29, 2023 |
Exhibit 99.2 CONFIDENTIAL - DO NOT DISTRIBUTE Morphimmune and Immunome Combined Corporate Presentation June 2023 CONFIDENTIAL - DO NOT DISTRIBUTE M O R P H I M M U N E + I M M U N O M E 2 Disclaimer and Forward-Looking Statements Disclosures For the purposes of this notice, the “presentation” that follows shall mean and include the slides that follow, the oral presentation of the slides by members |
|
| June 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2023 Immunome, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39580 77-0694340 (state or other jurisdiction of incorporation) (Commission File Numbe |
|
| June 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2023 Immunome, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39580 77-0694340 (state or other jurisdiction of incorporation) (Commission File Number |
|
| May 5, 2023 |
Immunome Reports First Quarter 2023 Financial Results Exhibit 99.1 Immunome Reports First Quarter 2023 Financial Results Exton, PA – May 5, 2023 – Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics to improve patient care, today reported financial results for the first quarter ended March 31, 2023 and provided a corporate update. “The e |
|
| May 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 |
|
| May 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2023 Immunome, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39580 77-0694340 (state or other jurisdiction of incorporation) (Commission File Number) |
|
| April 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934(Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defini |
|
| April 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934(Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defini |
|
| April 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934(Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defini |
|
| March 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2023 Immunome, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39580 77-0694340 (state or other jurisdiction of incorporation) (Commission File Numb |
|
| March 16, 2023 |
Exhibit 10.29 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IMMUNOME, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO IMMUNOME, INC. IF PUBLICLY DISCLOSED. COLLABORATION AND OPTION AGREEMENT by and between IMMUNOME, INC. AND ABBVIE GLOBAL ENTERPRISES LTD. Dated as of January 4, 2023 TAB |
|
| March 16, 2023 |
Exhibit 10.10 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IMMUNOME, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO IMMUNOME, INC. IF PUBLICLY DISCLOSED. AMENDMENT #2 TO EXCLUSIVE LICENSE AGREEMENT AMENDMENT #2 TO EXCLUSIVE LICENSE AGREEMENT (this “Amendment #3”) dated as of December |
|
| March 16, 2023 |
Amended and Restated Employment Agreement of Matthew Robinson effective June 16, 2022. Exhibit 10.21 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IMMUNOME, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO IMMUNOME, INC. IF PUBLICLY DISCLOSED. June 23, 2022 Matt Robinson, PhD. [***] [***] Re: Dear Matt: lmmunome, Inc. Employment Offer On behalf of Immunome, Inc. (the "Comp |
|
| March 16, 2023 |
Employment Agreement between the Company and Dennis Giesing effective April 7, 2021. Exhibit 10.20 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IMMUNOME, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO IMMUNOME, INC. IF PUBLICLY DISCLOSED. March 4, 2021 Dennis Giesing, Ph.D. [***] [***] Re:Immunome, Inc. Employment Offer Dear Dennis: On behalf of Immunome, Inc. (the “C |
|
| March 16, 2023 |
Immunome Reports Fourth Quarter and Full Year 2022 Financial Results Exhibit 99.1 Immunome Reports Fourth Quarter and Full Year 2022 Financial Results EXTON, Pa. – March 16, 2023 - Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics to improve patient care, today reported financial results for the fourth quarter ended December 31, 2022 and provided a c |
|
| March 16, 2023 |
Exhibit 10.12 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IMMUNOME, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO IMMUNOME, INC. IF PUBLICLY DISCLOSED. November 17, 2022 Whitehead Institute for Biomedical Research 455 Main Street Cambridge, MA 02142 Attn: Intellectual Property Offic |
|
| March 16, 2023 |
Exhibit 10.34 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IMMUNOME, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO IMMUNOME, INC. IF PUBLICLY DISCLOSED. Quotation & Contract of Sale Immunome, Inc. SERVICES Hybridoma screening QUOTE REFERENCE [***] EFFECTIVE DATE December 30, 2022 CON |
|
| March 16, 2023 |
Exhibit 10.32 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IMMUNOME, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO IMMUNOME, INC. IF PUBLICLY DISCLOSED. AMENDMENT #2 TO MASTER SERVICES AGREEMENT AMENDMENT #2 TO MASTER SERVICES AGREEMENT (this “Amendment”) dated as of January 1, 2022 |
|
| March 16, 2023 |
Exhibit 10.30 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IMMUNOME, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO IMMUNOME, INC. IF PUBLICLY DISCLOSED. MASTER SERVICES AGREEMENT THIS MASTER SERVICES AGREEMENT is made as of this 8th day of November, 2016 (the “Effective Date”) by and |
|
| March 16, 2023 |
Exhibit 10.24 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IMMUNOME, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO IMMUNOME, INC. IF PUBLICLY DISCLOSED. AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1. CONTRACT ID CODE PAGE OF PAGES 1 2 2. AMENDMENT/MODIFICATION NO. 3. EFFECTIVE |
|
| March 16, 2023 |
Exhibit 10.31 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IMMUNOME, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO IMMUNOME, INC. IF PUBLICLY DISCLOSED. Arrayjet Advance Contract for Immunome Inc. Revision to “Master Services Agreement” Date: 15th February 2021 Direct No:[***] Email: |
|
| March 16, 2023 |
As filed with the Securities and Exchange Commission on March 16, 2023 As filed with the Securities and Exchange Commission on March 16, 2023 Registration No. |
|
| March 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-39580 IMMUNOME, INC. (Exact name of registrant |
|
| March 16, 2023 |
Immunome, Inc. Up to $20,176,619 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-259966 PROSPECTUS SUPPLEMENT (To the Prospectus Supplement dated October 14, 2021 To the Prospectus dated October 14, 2021) Immunome, Inc. Up to $20,176,619 Common Stock This prospectus supplement amends and supplements the information in our prospectus dated October 14, 2021 (File No. 333-259966). This prospectus supplement should be read in c |
|
| March 16, 2023 |
EX-4.6 2 tmb-20221231xex4d6.htm EX-4.6 Exhibit 4.6 DESCRIPTION OF CAPITAL STOCK The following description of our capital stock, certain provisions of our Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”), our Amended and Restated Bylaws (“Bylaws”), and certain provisions of Delaware law are summaries. The following is qualified in its entirety by (i) our Certif |
|
| March 16, 2023 |
Exhibit 10.33 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IMMUNOME, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO IMMUNOME, INC. IF PUBLICLY DISCLOSED. AMENDMENT #3 TO MASTER SERVICES AGREEMENT AMENDMENT #3 TO MASTER SERVICES AGREEMENT (this “Amendment”) dated as of December 30, 202 |
|
| March 16, 2023 |
Exhibit 107 Form S-8 (Form Type) Immunome, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, par value $0.0001 per share 457(c) and 457(h) 1,211,958 (1) $ 4.32 |
|
| February 14, 2023 |
IMNM / Immunome Inc / Prentice Capital Management, LP - SC 13G/A Passive Investment SC 13G/A 1 tm236686d2sc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 SCHEDULE 13G (Amendment No. 2) IMMUNOME, INC. (Name of Issuer) Common Stock, Par Value $0.0001 Per Share (Title of Class of Securities) 45257U108 (CUSIP Number of Class of Securities) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| January 30, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2023 Immunome, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39580 77-0694340 (state or other jurisdiction of incorporation) (Commission File Nu |
|
| January 30, 2023 |
Exhibit 99.1 Harnessing the Power of the Human Memory B Cell JANUARY 2023 Immunome, Inc. 665 Stockton Drive, Suite 300 | Exton, PA 19341 610.321.3700 | immunome.com Copyright © 2023 Immunome, Inc. All rights reserved. 2 Disclaimers and Forward - Looking Statements Copyright © 2023 Immunome, Inc. All rights reserved. This presentation includes certain disclosures that contain “forward - looking sta |
|
| January 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Amendment No. 4 Under the Securities Exchange Act of 1934 IMMUNOME, INC. (Name of Issuer) Common stock, $0.0001 par value per share (Title of Class of Securities) 45257U108 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu |
|
| January 6, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2023 Immunome, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39580 77-0694340 (state or other jurisdiction of incorporation) (Commission File Num |
|
| January 6, 2023 |
Exhibit 99.1 PRESS RELEASE AbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets - Multi-year collaboration to identify up to 10 novel target-antibody pairs leveraging Immunome?s Discovery Engine - Immunome to receive $30M upfront payment with potential for further platform access and option payments as well as development, commercial, and sales-based mil |
|
| January 6, 2023 |
Exhibit 99.1 Harnessing the Power of the Human Memory B Cell JANUARY 2023 Immunome, Inc. 665 Stockton Drive, Suite 300 | Exton, PA 19341 610.321.3700 | immunome.com Copyright ? 2023 Immunome, Inc. All rights reserved. 2 Disclaimers and Forward - Looking Statements Copyright ? 2023 Immunome, Inc. All rights reserved. This presentation includes certain disclosures that contain ?forward - looking sta |
|
| January 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2023 Immunome, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39580 77-0694340 (state or other jurisdiction of incorporation) (Commission File Num |
|
| November 15, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2022 Immunome, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39580 77-0694340 (state or other jurisdiction of incorporation) (Commission File N |
|
| November 15, 2022 |
Presentation dated November 15, 2022. Exhibit 99.1 Harnessing the Human Cell the Power of Memory B November 15, 2022 Immunome, Inc. 665 Stockton Drive, Suite 300 | Exton, PA 19341 610.321.3700 | www.immunome.com Copyright ? 2022 Immunome, Inc. All rights reserved. Disclaimers and Forward-Looking Statements This presentation includes certain disclosures that contain ?forward-looking statements? intended to qualify for the ?safe harbor? |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 14, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 Immunome, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39580 77-0694340 (state or other jurisdiction of incorporation) (Commission File N |
|
| November 14, 2022 |
Immunome Reports Third Quarter 2022 Financial Results Exhibit 99.1 Immunome Reports Third Quarter 2022 Financial Results Exton, PA ? November 14, 2022 - Immunome, Inc. (Nasdaq: IMNM), a clinical stage biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update. ?We l |
|
| October 6, 2022 |
Letter from Deloitte & Touche LLP to the Securities and Exchange Commission, dated October 6, 2022 Exhibit 16.1 Deloitte & Touche LLP 1700 Market Street Philadelphia, PA 19103 USA Tel: 1 (215) 246-2300 Fax: 1 (215) 569 2441 www.deloitte.com October 6, 2022 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-7561 Dear Sirs/Madams: We have read Item 4.01 of Immunome, Inc.?s Form 8-K dated October 6, 2022, and we agree with the statements made therein. Yours truly, |
|
| October 6, 2022 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2022 Immunome, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39580 77-0694340 (State or other jurisdiction of incorporation) (Commission File |
|
| September 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 2, 2022 Immunome, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39580 77-0694340 (state or other jurisdiction of incorporation) (Commission File N |
|
| September 2, 2022 |
Letter to Holders of Series B Warrants to Purchase Shares of Common Stock. Exhibit 10.1 September 2, 2022 Re: Series B Warrants to Purchase Shares of Common Stock dated as of April 28, 2021 Dear Warrant Holder: Immunome, Inc. (the ?Company?) previously issued certain Series B Warrants (the ?Series B Warrants?) to purchase shares of the Company?s common stock, par value $0.0001 per share (?Common Stock?) pursuant to a Securities Purchase Agreement dated April 26, 2021 by |
|
| August 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
